SCHEMBL1337166

SCHEMBL1337166

COC(=O)c1cc(-c2ccc3c(c2)c2cc(-c4ccc(Cl)cc4Cl)c(=O)n(C)c2n3C)[nH]n1

nearest known ligand 0.40

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
▸ ALPL P05186 1/20 0.40
▸ CNR1 P21554 13/20 0.38
▸ CNR2 P34972 12/20 0.38
▸ GABRA1 P14867 2/20 0.36
▸ ADRA2C P18825 2/20 0.36
▸ SLC6A3 Q01959 2/20 0.36
▸ EGFR P00533 1/20 0.36
▸ ALOX5 P09917 1/20 0.36
▸ ADORA3 P0DMS8 1/20 0.36
▸ MAPK3 P27361 1/20 0.36
▸ OPRL1 P41146 1/20 0.36
▸ SLC18A2 Q05940 1/20 0.36
▸ MAPK14 Q16539 1/20 0.36
▸ TMEM97 Q5BJF2 1/20 0.36
▸ SIGMAR1 Q99720 1/20 0.36
▸ GABRA2 P47869 1/20 0.35
▸ GABRB2 P47870 1/20 0.35
▸ MAP2K4 P45985 1/20 0.35
▸ MEN1 O00255 1/20 0.35
▸ KMT2A Q03164 1/20 0.35

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL1337456 0.90 MARS1 (0.38) ALPLCNR1CNR2GABRA1ADRA2C
SCHEMBL1336848 0.85 CNR1 (0.38) CNR1CNR2GABRA1ADRA2CSLC6A3
SCHEMBL1339276 0.84 MKNK1 (0.43) CNR1CNR2GABRA1ADRA2CSLC6A3
SCHEMBL1339405 0.83 NOTUM (0.49) CNR1CNR2MEN1KMT2AMAPT
SCHEMBL1338782 0.83 CNR1 (0.37) ALPLCNR1CNR2GABRA1ADRA2C
SCHEMBL1339591 0.80 MAPT (0.42) ALPLCNR1CNR2GABRA1SLC6A3
SCHEMBL1339414 0.80 GABRG2 (0.43) CNR1CNR2GABRA1
SCHEMBL1338161 0.80 CNR1 (0.35) ALPLCNR1CNR2GABRA1ADRA2C
SCHEMBL1338074 0.80 L3MBTL1 (0.40) CNR1CNR2GABRA1ADRA2CSLC6A3
SCHEMBL1339349 0.78 KDM4E (0.36) ALPLCNR1CNR2GABRA1ADRA2C

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-8063061-B2 6-(2-amino-1,3-thiazol-4-yl)-3-(2,4-dichlorophenyl)-1-methyl-1,9-dihydro-2H-pyrido[2,3-b]indol-2-one; affinity for GABAA-receptor-associated omega modulatory sites SANOFI-AVENTIS (FR) 2011-11-22 — — US disclosed
US-20080262020-A1 6-Heteroarylpyridoindolone Derivatives, Their Preparation and Therapeutic Use Thereof SANOFI-AVENTIS (FR) 2008-10-23 — — US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20080262020-A1 6-Heteroarylpyridoindolone Derivatives, Their Preparation and Therapeutic Use Thereof CYP11B2, CYP11B1, CYP2D6 ALPL 3202/4885CNR1 262/4885CNR2 299/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.

Send feedback